Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

The "43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025" report has been added to ResearchAndMarkets.com's offering.The 43rd Annual JP Morgan Healthcare Conference took place in San ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Foster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir-the company’s twice-yearly ...

Gilead and the Gilead logo, Truvada, and Truvada for PrEP are registered trademarks ... PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest ...

Innovative Chronic Pain Treatment Receives IP Protection in India's $55 Billion Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB, Feb. 18, 2025 /PRNewswire/ -- Innocan Pharma Corporation ...